Survodutide is a dual GLP-1 and glucagon receptor agonist under investigation for treating obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH), also known as fatty liver disease.  Its unique mechanism targets multiple pathways to deliver broad metabolic benefits. 
Significant Weight Loss: In Phase 2 trials, participants lost up to 18.7% of body weight over 46 weeks, with up to 40% achieving at least 20% weight loss—a result comparable to or greater than leading GLP-1 therapies. 
Improved Metabolic Health: Survodutide enhances glycemic control, reducing HbA1c levels by up to 1.71%, and improves insulin sensitivity and lipid profiles. 
Liver Health Benefits: It shows strong potential for treating MASH, with up to 83% of participants achieving MASH resolution without worsening fibrosis after 48 weeks.  It reduces liver fat, fibrosis, and inflammation.
Increased Energy Expenditure: Unlike GLP-1-only drugs, glucagon receptor activation boosts thermogenesis and fat oxidation, helping overcome metabolic slowdown during weight loss. 
Cardiometabolic Protection: By reducing visceral fat, improving liver health, and lowering systemic inflammation, Survodutide may reduce cardiovascular risk factors, including those linked to heart failure with preserved ejection fraction. 
While side effects like nausea, vomiting, and diarrhea are common—especially during dose escalation—they are generally mild and decrease over time. Survodutide is currently in Phase 3 clinical trials, with potential approval and market launch expected between 2027 and 2028.